MHC Class I Antigen Presentation

Your immune system is a relentless surveillance network, and its most critical task is distinguishing your healthy cells from those compromised by intracellular threats like viruses or cancerous mutations. The MHC class I antigen presentation pathway is the fundamental mechanism that enables this distinction. It acts as a constant cellular report card, displaying fragments of proteins made inside the cell on the surface for inspection by CD8+ cytotoxic T cells. Understanding this pathway is essential for grasping how we fight intracellular infections, why transplanted organs are rejected, and the basis for revolutionary cancer immunotherapies.

The Cellular Context and Key Players

MHC class I molecules are transmembrane glycoproteins expressed on the surface of virtually all nucleated cells in the body. This universal expression is crucial—it means every cell has the potential to announce if it has been hijacked or transformed from within. The structure of an MHC class I molecule is a key to its function. It is composed of two non-covalently linked chains: a polymorphic heavy chain (encoded within the Major Histocompatibility Complex) and a smaller, invariant chain called beta-2 microglobulin (β2M). The heavy chain forms a peptide-binding groove that can hold a short peptide, typically 8-10 amino acids long.

The critical reader of these displayed peptides is the CD8+ cytotoxic T lymphocyte (CTL). These immune cells possess T-cell receptors (TCRs) that are specifically designed to recognize peptide fragments cradled within the MHC class I groove. The CD8 co-receptor on the T cell binds to a conserved portion of the MHC class I molecule, stabilizing this interaction. If the TCR recognizes the presented peptide as foreign or abnormal—such as a viral protein or a mutated cancer antigen—the CD8+ T cell becomes activated and initiates the destruction of the presenting cell. Think of MHC class I as a universal display rack and the CD8+ T cell as a security inspector; if the displayed item (peptide) is on the "wanted" list, the cell (the shop) is shut down.

The Endogenous Pathway: From Protein to Peptide Display

The journey of a peptide from inside the cytosol to the cell surface is a tightly regulated, multi-step process known as the endogenous pathway. This pathway specializes in sampling the cell's internal protein content.

1. Proteasomal Degradation: The process begins in the cytosol. Cellular proteins, including normal self-proteins, misfolded proteins, and viral or tumor proteins, are tagged for destruction with a small protein called ubiquitin. These tagged proteins are fed into a large multi-subunit protease complex called the proteasome. The proteasome chops these proteins into small peptide fragments, typically 8-10 amino acids in length, which are ideal for fitting into the MHC class I binding groove.

2. Peptide Transport into the ER: The newly generated peptides in the cytosol must enter the endoplasmic reticulum (ER), where MHC class I molecules are assembled. This transport is the job of a dedicated heterodimeric pump called the Transporter Associated with antigen Processing (TAP). TAP is embedded in the ER membrane and uses ATP to selectively shuttle peptides from the cytosol into the ER lumen. It has a preference for peptides of the correct length and carboxyl-terminal, acting as a key checkpoint in the pathway.

3. MHC Class I Assembly and Peptide Loading: Inside the ER, the MHC class I heavy chain is synthesized and binds to β2M. However, this empty complex is unstable. A multi-protein complex called the peptide-loading complex, which includes TAP, chaperone proteins like calnexin and calreticulin, and the oxidoreductase ERp57, facilitates the loading of a peptide into the binding groove. The binding of a suitable peptide stabilizes the entire MHC class I structure. This "peptide editing" ensures that only stable, peptide-loaded complexes exit the ER.

4. Surface Expression: The stable, peptide-loaded MHC class I-β2M complex is packaged into vesicles, trafficked through the Golgi apparatus, and finally delivered to the cell surface. Here, it is displayed for scrutiny by circulating CD8+ T cells. The entire process, from protein degradation to surface display, is continuous, providing a real-time snapshot of the cell's interior.

Immunological Significance and Cross-Presentation

The primary role of this pathway is immune surveillance against intracellular pathogens and malignant transformation. When a virus infects a cell, viral proteins are synthesized in the cytosol, degraded, and presented on MHC class I. This flags the cell as infected, leading to its elimination by CTLs before it can produce more virus particles. Similarly, cancer cells often produce mutated or overexpressed proteins (neoantigens) that are processed and presented, marking the tumor cell for destruction.

A critical adaptation of this system is a process called cross-presentation. While MHC class I typically presents endogenous peptides, specialized antigen-presenting cells (APCs), particularly dendritic cells, can "cross-present" exogenous antigens (e.g., from a dead virus-infected cell they have phagocytosed) on their own MHC class I molecules. This is essential for initiating CD8+ T cell responses against pathogens that do not directly infect APCs. The dendritic cell can ingest an infected cell, process the viral antigens, and present them via MHC I to "cross-prime" naïve CD8+ T cells, launching a systemic adaptive immune response.

Clinical Connections and Therapeutic Implications

Dysfunction in the MHC class I pathway has profound clinical consequences. Many viruses (e.g., Cytomegalovirus, HIV) have evolved sophisticated mechanisms to evade detection by downregulating MHC class I expression or inhibiting TAP function. This allows them to hide from CD8+ T cells, establishing persistent infections.

In transplantation, MHC class I molecules are the major targets of rejection. These proteins are highly polymorphic (highly variable between individuals), so a recipient's immune system will recognize donor MHC class I as foreign, triggering a powerful CTL response against the grafted organ. This is why meticulous histocompatibility matching is vital.

Conversely, enhancing MHC class I presentation is the goal of several cancer immunotherapies. Checkpoint inhibitors, such as anti-PD-1 drugs, work by removing the "brakes" on CD8+ T cells that have recognized tumor antigens presented on MHC class I, allowing them to attack cancer cells more effectively. Cancer vaccines and adoptive T-cell therapies aim to boost the number or effectiveness of CTLs that target specific tumor-associated peptides presented by MHC class I.

Common Pitfalls

1. Confusing MHC Class I with Class II: A classic exam trap. Remember: MHC class I presents endogenous peptides to CD8+ T cells on all nucleated cells. MHC class II presents exogenous peptides to CD4+ T cells on professional antigen-presenting cells (macrophages, dendritic cells, B cells). Mnemonic: "CD8 kills" (Class I) and "CD4 helps" (Class II).
2. Overgeneralizing Cell Expression: Stating that MHC class I is on "all cells" is incorrect. They are on all nucleated cells. The significant exception is the anucleate red blood cell (RBC), which lacks MHC class I (and II). This is why RBCs have different blood group antigens.
3. Misidentifying the Peptide Source: Assuming MHC class I can present peptides from extracellular bacteria it engulfs is a mistake. The default, canonical pathway is strictly for proteins synthesized within that specific cell's cytosol. The presentation of external antigens on MHC I is the special, non-canonical role of cross-presentation in dendritic cells.
4. Ignoring the Role of β2-Microglobulin: It's easy to focus solely on the polymorphic heavy chain, but β2M is essential for stable MHC class I expression. Without it, the heavy chain cannot exit the ER. Deficiencies in β2M lead to a severe lack of surface MHC class I molecules.

Summary

• MHC class I molecules are expressed on all nucleated cells and function as display platforms for peptides derived from proteins synthesized inside that cell (endogenous pathway).
• The pathway involves: cytosolic protein degradation by the proteasome, peptide transport into the endoplasmic reticulum by TAP transporters, and assembly of the peptide with the MHC I heavy chain and beta-2 microglobulin to form a stable complex for surface expression.
• These peptide-MHC I complexes are surveyed by CD8+ cytotoxic T cells. Recognition of a non-self peptide (e.g., from a virus or tumor) triggers the destruction of the presenting cell.
• Cross-presentation by dendritic cells is a crucial exception, allowing exogenous antigens to be presented on MHC class I to activate naïve CD8+ T cells.
• Clinically, this pathway is central to antiviral and anti-tumor immunity, organ transplant rejection, and the mechanism of action for cutting-edge cancer immunotherapies like checkpoint inhibitors.